Background

The microbiome significantly impacts human health and has been linked to the development of many diseases, including cancer and infectious disease. More recently, clinical data has demonstrated that antibiotic treatment can significantly influence the outcome of cancer immunotherapy. Initial mouse studies have suggested that therapeutic intervention to optimize microbiota composition can improve immunotherapy outcome. More work is needed to translate these preclinical findings into the clinic.

Technology Overview

Researchers at Mount Sinai have isolated and identified a novel strain of E. Coli that is able to induce expansion of Th17 T-cells in the colonic lamina propia of mice. This strain could be used as part of a biologic/therapeutic agent to augment response to immunotherapy.

Stage of Development

Ongoing in preclinical vivo studies to understand the effect of the microbiome on immunotherapy resistance and the potential for therapeutic intervention

Applications

Augment response to immunotherapy

Live Biotherapeutic to Augment Response to Immunotherapy

IP Status